Livnat Jerby is an Assistant Professor in the Department of Genetics at Stanford University, a Chan Zuckerberg Biohub Investigator, and a Paul Allen Distinguished Investigator. Her research integrates latest advances in genetic editing, single cell and spatial genomics to identify new immunomodulating mechanisms and interventions. Recent work from her lab provides an unprecedented view of the cancerimmune interplay directly in patients and her team is now developing new cell engineering technologies to track and trigger targeted immune responses with spatial, temporal, and cellular specificity. Prior to joining Stanford, Livnat was a postdoctoral fellow in Aviv Regev’s lab at the Broad Institute of MIT and Harvard, where she used single cell genomics to identify regulators of T cell exclusion and resistance to immune checkpoint blockade. Livnat holds a B.Sc. in Computer Science and Biology and obtained her PhD in 2016 from Tel Aviv University, where she worked with Eytan Ruppin, studying genetic interactions in cancer. Her research has been generously supported by the Cancer Research Institute (CRI), the Burroughs Wellcome Fund (BWF), Schmidt Family Foundation, Rothschild Foundation, Ovarian Cancer Research Alliance (OCRA), Paul G. Allen Family Foundation, Bill and Melinda Gates Foundation, National Institute of Health (NIH), and Chan Zuckerberg Biohub Initiative.